Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03686332
Other study ID # N18PER
Secondary ID 2018-000603-17
Status Completed
Phase Phase 2
First received
Last updated
Start date September 25, 2018
Est. completion date September 15, 2023

Study information

Verified date September 2023
Source The Netherlands Cancer Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients with advanced penile cancer have a poor prognosis (21% 2-year overall survival from moment of diagnosis) and high morbidity due to progressive locoregional disease. Translational studies show high rates of infiltrating immune cells and PD-L1 positivity, suggesting that immunotherapy may be beneficial in this disease. Atezolizumab, targeting PD-L1, is active in several cancer types and is generally well-tolerated. This study will investigate whether atezolizumab can be combined with radiotherapy to control locoregional lymph node disease. Furthermore, the activity of atezolizumab in advanced penile cancer patients will be investigated.


Description:

Rationale Patients with advanced penile cancer have a poor prognosis (21% 2-year overall survival from moment of diagnosis) and high morbidity due to progressive locoregional disease. Translational studies show high rates of infiltrating immune cells and PD-L1 positivity, suggesting that immunotherapy may be beneficial in this disease. Atezolizumab, targeting PD-L1, is active in several cancer types and is generally well-tolerated. This study will investigate whether atezolizumab can be combined with radiotherapy to control locoregional lymph node disease. Furthermore, the activity of atezolizumab in advanced penile cancer patients will be investigated. Objectives: 1. Efficacy of atezolizumab in advanced penile cancer patients. 2. Feasibility of a protracted schedule of radiotherapy on locoregional disease in combination with immunotherapy for advanced penile cancer Study design: Single-center, nonrandomized, Phase 2 study with 2 treatment arms. Study population: Men, ≥18 years of age, with advanced inoperable penile cancer, N=32. Intervention: All patients will receive atezolizumab, 1200 mg, every 3 weeks, by IV infusion. Patients in group A will additionally receive 33 fractions of 1.5 (locoregional affected lymph nodes) and 1.8 Gy (tumor+margin) irradiation, concurrently with atezolizumab treatment. Primary endpoint: Progression-free survival at 1 year. Main secondary endpoint: 2-year overall survival rate of the complete study population. Percentage of patients who complete the full course of radiotherapy in the radiotherapy/atezolizumab arm. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Patients will be treated every 3 weeks with atezolizumab for one year or until loss of clinical benefit. Atezolizumab is generally well tolerated although immune-related toxicity does occur. Toxicity of combining atezolizumab with a long course of radiotherapy is unknown and may result in increased toxicity. It is unknown whether atezolizumab will induce responses in patients with advanced penile cancer.


Recruitment information / eligibility

Status Completed
Enrollment 32
Est. completion date September 15, 2023
Est. primary completion date September 28, 2022
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: - Written informed consent, prior to performing any protocol-related procedures, including screening evaluations. - Age > 18 years at time of study entry. - Advanced histologically documented, squamous cell carcinoma of the penis or distal urethra. Advanced disease is defined as: - Distant metastases, OR - LRAPC, defined as a large or inoperable primary tumor (T4), palpable nodes >3cm in diameter or fixed nodes, suspicion of extra-nodal extension or pelvic node involvement (N2/N3) - Arm A: Locoregional disease (with or without distant metastases), likely to derive benefit from locoregional radiotherapy and not previously treated with radiotherapy. - Arm B: Benefit of locoregional radiotherapy unlikely OR previously treated with irradiation. - World Health Organisation (WHO) performance status of 0 or 1. - Life expectancy of > 12 weeks. - Adequate normal organ and marrow function as defined below: - Haemoglobin = 5.6/mmol/L - White blood cell count (WBC) = 2 x 109/L - Absolute neutrophil count (ANC) = 1.5 x 109/L - Platelet count = 100 x 109/L (>100,000 per mm3) - Serum bilirubin = 1.5 x institutional upper limit of normal (ULN). This will not apply to subjects with confirmed Gilbert's syndrome, who will be allowed in consultation with a study physician. - AST/ALT = 2.5 x institutional ULN unless liver metastases are present, in which case it must be = 5x ULN. - Serum creatinine clearance >30 mL/min by calculation with the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection measurement. Exclusion Criteria: - Involvement in the planning and/or conduct of the study (applies to both Roche staff and/or staff at the study site) or previous enrolment in the present study. - Participation in another clinical study with an investigational product during the last 4 weeks - Any previous treatment with a PD-1 or PD-L1 inhibitor - History of another primary malignancy except for: - Malignancy treated with curative intent and with no known active disease =2 years before the first dose of study drug - Low potential risk of 3-year cancer-specific death (estimated<5%), including adequately treated non-melanoma skin cancer without evidence of disease, adequately treated carcinoma in situ without evidence of disease, or localized prostate cancer treated with curative intent and absence of prostate-specific antigen (PSA) relapse or incidental prostate cancer (Gleason score = 7 and PSA < 10 ng/mL) undergoing active surveillance. - Treatment with the last dose of any systemic anti-cancer therapy = 21 days prior to the first dose of study drug. Local treatment of isolated lesions for palliative intent is acceptable (eg, local surgery or radiotherapy). - Current or prior use of immunosuppressive medication within 14 days before the first dose of study drug, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at doses =10 mg/day of prednisone, or an equivalent corticosteroid. - History of primary immunodeficiency, allogeneic organ transplant or autoimmune disease, including - but not limited to - myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis. Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone will not be excluded from this study. Patients with controlled diabetes mellitus type I on a stable dose of insulin regimen may be eligible for this study. - Uncontrolled significant intercurrent illness, including - but not limited to - ongoing or active infection (including acute or chronic hepatitis B, hepatitis C or human immunodeficiency virus (HIV)), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent - Known active tuberculosis - Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results - Brain metastases or leptomeningeal disease. Inclusion of patients with brain metastases is allowed if patients have been adequately treated, are not symptomatic and show no signs of progression on brain imaging 28 days after completion of treatment (including surgery, radiotherapy or treatment with systemic corticosteroids). - Subjects with uncontrolled seizures.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Arm A: Atezolizumab and Radiotherapy
patients will receive atezolizumab, 1200 mg, every 3 weeks, by IV infusion. Patients in group A will additionally receive 33 fractions of 1.5 (locoregional affected lymph nodes) and 1.8 Gy (tumor+margin) irradiation, concurrently with atezolizumab treatment.
Arm B: Atezolizumab
patients will receive atezolizumab, 1200 mg, every 3 weeks, by IV infusion.

Locations

Country Name City State
Netherlands Netherlands Cancer Institute - Antoni van Leeuwenhoek Amsterdam Noord- Holland

Sponsors (2)

Lead Sponsor Collaborator
The Netherlands Cancer Institute Hoffmann-La Roche

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-free survival at 1 year. Progression-free survival at 1 year. 1 year
Secondary 2-year overall survival rate of the complete study population. The key secondary outcome measure will be 2-year overall survival rate in the full study cohort (Arm A and B combined).
radiotherapy/atezolizumab arm.
2 year
See also
  Status Clinical Trial Phase
Completed NCT05518201 - Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old Phase 1
Recruiting NCT04708470 - A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers Phase 1/Phase 2
Active, not recruiting NCT04357873 - Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations Phase 2
Terminated NCT00058448 - S0224, Docetaxel in Treating Patients With Locally Advanced or Metastatic Penile Cancer (TERMINATED) Phase 2
Recruiting NCT02817958 - Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis Phase 2
Completed NCT02280811 - T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers Phase 2
Recruiting NCT02994758 - Development of Diagnostics and Treatment of Urological Cancers N/A
Completed NCT00019110 - Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer Phase 1
Completed NCT04574427 - INtra-operative Evaluation of a Novel FLUorescENt C-mEt Tracer in Penile and Tongue
Recruiting NCT02012699 - Integrated Cancer Repository for Cancer Research
Recruiting NCT05946993 - Linking In With Advice and Supports for Men Impacted by Metastatic Cancer N/A
Recruiting NCT04028479 - The Registry of Oncology Outcomes Associated With Testing and Treatment
Recruiting NCT05686226 - E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers Phase 2
Completed NCT05376202 - Image Guided Penile Cancer Surgery Phase 1
Recruiting NCT05264337 - Lymphedema After Urologic Surgery
Recruiting NCT03774901 - Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma Phase 2
Completed NCT01209325 - Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males Phase 2
Recruiting NCT05592639 - VideoEndoscopic Radical Inguinal Lymphadenectomy for Penile Cancer N/A
Completed NCT00066391 - Irinotecan and Cisplatin in Treating Patients With Locally Advanced or Metastatic Penile Cancer Phase 2
Not yet recruiting NCT06353906 - Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer Phase 2